Company intelligence / Profile preview

Recida Therapeutics

Menlo Park, California, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 1

Overview

Recida Therapeutics is developing RC-01, an IND-stage LpxC inhibitor with broad-spectrum bactericidal activity against major multidrug-resistant gram-negative pathogens. Preclinical data show favorable pharmacokinetics and safety. The company has received funding from CARB-X to advance this program into clinical development

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (specifically LpxC inhibitors)
Industry: Biotech

Drug pipeline

1 asset

RC-01

Partnerships

CARB-X funding partnership for antibiotic development

Beyond the preview

Go deeper on Recida Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recida Therapeutics.

Explore the full profile